rs56362165

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_016507.4(CDK12):​c.3566T>A​(p.Leu1189Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00139 in 1,614,206 control chromosomes in the GnomAD database, including 24 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L1189R) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0070 ( 14 hom., cov: 32)
Exomes 𝑓: 0.00081 ( 10 hom. )

Consequence

CDK12
NM_016507.4 missense

Scores

18

Clinical Significance

Likely benign criteria provided, multiple submitters, no conflicts B:3O:1

Conservation

PhyloP100: 0.557

Publications

8 publications found
Variant links:
Genes affected
CDK12 (HGNC:24224): (cyclin dependent kinase 12) Enables RNA polymerase II CTD heptapeptide repeat kinase activity and cyclin binding activity. Involved in phosphorylation of RNA polymerase II C-terminal domain; protein autophosphorylation; and regulation of MAP kinase activity. Located in nuclear speck. Part of cyclin K-CDK12 complex. [provided by Alliance of Genome Resources, Apr 2022]
CDK12 Gene-Disease associations (from GenCC):
  • Tourette syndrome
    Inheritance: Unknown Classification: NO_KNOWN Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0021578074).
BP6
Variant 17-39526122-T-A is Benign according to our data. Variant chr17-39526122-T-A is described in ClinVar as Likely_benign. ClinVar VariationId is 133860.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00698 (1063/152312) while in subpopulation AFR AF = 0.0246 (1022/41562). AF 95% confidence interval is 0.0233. There are 14 homozygotes in GnomAd4. There are 482 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 14 Unknown gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDK12NM_016507.4 linkc.3566T>A p.Leu1189Gln missense_variant Exon 13 of 14 ENST00000447079.6 NP_057591.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDK12ENST00000447079.6 linkc.3566T>A p.Leu1189Gln missense_variant Exon 13 of 14 1 NM_016507.4 ENSP00000398880.4
CDK12ENST00000430627.6 linkc.3566T>A p.Leu1189Gln missense_variant Exon 13 of 14 1 ENSP00000407720.2
CDK12ENST00000584632.5 linkc.3563T>A p.Leu1188Gln missense_variant Exon 13 of 13 5 ENSP00000464641.1
CDK12ENST00000559663.2 linkn.3566T>A non_coding_transcript_exon_variant Exon 13 of 21 5 ENSP00000453329.2

Frequencies

GnomAD3 genomes
AF:
0.00697
AC:
1061
AN:
152194
Hom.:
14
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0246
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00144
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000103
Gnomad OTH
AF:
0.00574
GnomAD2 exomes
AF:
0.00180
AC:
452
AN:
251326
AF XY:
0.00131
show subpopulations
Gnomad AFR exome
AF:
0.0246
Gnomad AMR exome
AF:
0.00101
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000114
Gnomad OTH exome
AF:
0.000652
GnomAD4 exome
AF:
0.000809
AC:
1182
AN:
1461894
Hom.:
10
Cov.:
32
AF XY:
0.000682
AC XY:
496
AN XY:
727248
show subpopulations
African (AFR)
AF:
0.0281
AC:
941
AN:
33480
American (AMR)
AF:
0.00105
AC:
47
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.0000116
AC:
1
AN:
86258
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53420
Middle Eastern (MID)
AF:
0.000520
AC:
3
AN:
5768
European-Non Finnish (NFE)
AF:
0.0000746
AC:
83
AN:
1112012
Other (OTH)
AF:
0.00177
AC:
107
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
80
160
241
321
401
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
34
68
102
136
170
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00698
AC:
1063
AN:
152312
Hom.:
14
Cov.:
32
AF XY:
0.00647
AC XY:
482
AN XY:
74494
show subpopulations
African (AFR)
AF:
0.0246
AC:
1022
AN:
41562
American (AMR)
AF:
0.00144
AC:
22
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3466
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5188
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4826
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10628
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000103
AC:
7
AN:
68026
Other (OTH)
AF:
0.00568
AC:
12
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
45
90
136
181
226
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00113
Hom.:
0
Bravo
AF:
0.00824
ESP6500AA
AF:
0.0236
AC:
104
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.00220
AC:
267
EpiCase
AF:
0.00
EpiControl
AF:
0.000119

ClinVar

Significance: Likely benign
Submissions summary: Benign:3Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

CDK12-related disorder Benign:1
Mar 08, 2019
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Hereditary breast ovarian cancer syndrome Benign:1
Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Other:1
Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.049
BayesDel_addAF
Benign
-0.47
T
BayesDel_noAF
Benign
-0.43
CADD
Benign
12
DANN
Benign
0.89
DEOGEN2
Benign
0.0052
T;.;T
Eigen
Benign
-0.94
Eigen_PC
Benign
-0.83
FATHMM_MKL
Benign
0.15
N
LIST_S2
Benign
0.65
T;T;T
MetaRNN
Benign
0.0022
T;T;T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
-1.1
.;N;N
PhyloP100
0.56
PrimateAI
Benign
0.33
T
PROVEAN
Benign
0.70
.;N;N
REVEL
Benign
0.12
Sift
Benign
0.43
.;T;T
Sift4G
Benign
0.67
T;T;T
Polyphen
0.0
.;B;B
Vest4
0.18, 0.16
MVP
0.21
MPC
0.19
ClinPred
0.0084
T
GERP RS
-0.036
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.2
Varity_R
0.042
gMVP
0.22
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs56362165; hg19: chr17-37682375; COSMIC: COSV104713510; API